Evidence map›Paper›PMID 29766318›Full record

Trial reportWorld journal of urology2018

A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms.

Mohamed Tharwat, Mohamed M Elsaadany, Ahmed M Lashin, Ahmed R El-Nahas

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02345980 (A Randomized Controlled Trial Evaluating Sildenafil Citrate in Relieving Ureteral Stent Related Symptoms), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02345980 phase4completednot on this map

A Randomized Controlled Trial Evaluating Sildenafil Citrate in Relieving Ureteral Stent Related Symptoms

TypeinterventionalSponsorMansoura UniversityRan2014 to 2016Enrolled94ConditionsQuality of LifeArmsSildenafil, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Observational
  6. Pharmacological treatment of bladder stent symptoms.Bladder (San Francisco, Calif.) · 2024
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mohamed TharwatUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Mohamed M ElsaadanyUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ahmed M LashinUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Ahmed R El-NahasUrology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt. ar_el_nahas@yahoo.com.ORCID http://orcid.org/0000-0001-7366-7306
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the role of sildenafil in relieving ureteral stent symptoms. PATIENTS AND

methodsA randomized controlled trial was conducted between March 2014 and November 2016. It included adult men who underwent unilateral ureteric stent after ureteroscopy. Patients who were taking PDE5-Is, alpha-blockers or anticholinergics, had contraindication to sildenafil or developed postoperative complications were not included. Eligible patients were randomized using sealed closed envelops to one of two groups (S and C). Patients in group S received sildenafil citrate 50 mg tablet once daily. Patients in group C were the control. All patients answered the ureteral stent symptom questionnaire (USSQ) after 2 weeks of stenting. Primary outcome was the difference in total USSQ score between both groups. Secondary outcomes were tolerability of the treatment and the difference in each domain of USSQ score.

resultsAfter randomization, four patients (7.3%) in group C withdraw their consent because of severe symptoms and two patients (3.6%) in group S discontinued treatment because of headache and dizziness. Final analysis was performed for 46 and 48 patients in groups C and S, respectively. Total USSQ score and all domains (except work performance) were significantly lower in group S (P < 0.001). Dysuria and urgency were significantly more in group C (P = 0.012 and 0.007, respectively). Three patients in groups S (6.25%) experienced transient mild adverse effects (dyspepsia, flushing and rhinitis in one patient for each) but they continued sildenafil.

conclusionsSildenafil is an effective and well-tolerated treatment option for relieving ureteral stent-related symptoms in men. CLINICALTRIAL. GOV IDENTIFIER: NCT02345980.

Indexed as

StentsUreteroscopyAdultDysuriaHematuriaHumansLower Urinary Tract SymptomsMaleMiddle AgedNocturiaPhosphodiesterase 5 InhibitorsPostoperative ComplicationsQuality of LifeSildenafil CitrateSurveys and QuestionnairesTreatment OutcomePhosphodiesterase 5 InhibitorsSildenafil CitratePDE5 inhibitor, quality of lifeSildenafilUreteral stentUreteric stent

Identifiers

PMID29766318
OpenAlexW2804304090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.